MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy

ABSTRACT: We aimed to restore MHC-I expression on the surface of solid tumors including breast cancer and melanoma cells to regain sensitivity to immunotherapy and suppress metastatic progression. We screened a natural compound library and identified macbecin II as a reagent that upregulates MHC-I expression and induces antigen-dependent cell death in pre-invasive and invasive breast cancer models. Furthermore, we employed active immunotherapy using engineered small extracellular vesicles from dendritic cells (DCs) as a tumor vaccine (IL2-ep13nsEV) in combination with macbecin II for personalized breast cancer treatment. We found that macbecin II induced MHC-I-dependent antigen presentation and that IL2-ep13nsEV synergized with macbecin II inducing cell death, reducing metastasis, and boosting immun

SUBMITTER: Ravindra Despande 

PROVIDER: S-SCDT-10_1038-S44321-025-00213-7 | biostudies-other |

REPOSITORIES: biostudies-other